Clinical Trials · NCT01769378
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 300
- Start date
- Jan 2013
- Locations
- 31 sites, 8 countries
- Primary endpoint
- Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks